

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO				Complete if Known		
				Application No.	10/799,163	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Filing Date	03/12/2004	
				First Named Inventor	John W. Holaday	
				Group Art Unit	1653	
				Examiner Name	Unassigned	
				Attorney Docket Number	05213-0077 (43170-296614)	
Sheet		of	4			
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
CY	1	5,252,718	A	Baird et al.	10/12/1993	
	2	5,288,704	A	Ungheri et al.	02/22/1994	
	3	5,629,327		D'Amato	05/13/1997	
	4	5,639,725		O'Reilly et al.	06/17/1997	
	5	5,733,876		O'Reilly et al.	03/31/1998	
	6	5,792,845		O'Reilly et al.	08/11/1998	
	7	5,854,205		O'Reilly et al.	12/29/1998	
	8	5,919,459	A	Nacy et al.	07/06/1999	
	9	6,346,510	B1	O'Reilly et al.	02/12/2002	
CY	10	6,413,513	B1	Holaday, John	07/02/2002	

Examiner Signature	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006
-----------------------	---------------------------------	--------------------	------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)					Complete if Known					
					Application No.		10/799,163			
					Filing Date		03/12/2004			
					First Named Inventor		John W. Holaday			
					Group Art Unit		1653			
					Examiner Name		Unassigned			
Sheet	2	of	4	Attorney Docket Number					05213-0077 (43170-296614)	
<b>FOREIGN PATENT DOCUMENTS</b>										
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>		
		Office <sup>2</sup>	Number <sup>3</sup>	Kind Code <sup>5</sup> (if known)						
CY	11	EP	0281822	A2	Takeda Chemical Industries, Ltd.	09/14/1988				
CY	12	EP	0657175	A2	Centro de Immunologia Molecular	06/14/1995				
CY	13	Japa	09316000	A	Toagosei Co. Ltd.	09/12/1997				
CY	14	WO	94/21288	A1	Assay Research, Inc.	09/29/1994				
CY	15	WO	94/27635	A	EntreMed, Inc.	12/08/1994				
CY	16	WO	99/45018	A1	Imclone Systems Incorporated	09/10/1999				

Examiner Signature	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006
-----------------------	---------------------------------	--------------------	------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application No.	10/799,163
		Filing Date	03/12/2004
		First Named Inventor	John W. Holaday
		Group Art Unit	1653
		Examiner Name	Unassigned
Sheet	3	of	4
Attorney Docket Number 05213-0077 (43170-296614)			
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
CY	17	Author: BAIRD et al. Title: Receptor- and Heparin-Binding Domains of Basic Fibroblast Growth Factor Publ: <u>Proceedings of the National Academy of Sciences</u> Vol/Iss: 85 Pages: 2324-2328 Date: 04/1988	
CY	18	Author: BALIAN et al. Title: Structure of Rat Skin Collagen $\alpha$ 1-CB8. Amino Acid Sequence of the Hydroxylamine-Produced Fragment HA2 Publ: <u>Biochemistry</u> Vol/Iss: 11 (20) Pages: Date:	
CY	19	Author: ENJOJI, K. et al. Title: Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly <sup>132</sup> -Phe <sup>140</sup> , of the third Kunitz Domain is a Heparin-Binding Site Publ: <u>Biochemistry</u> Vol/Iss: 34 (17) Pages: 5725-5735 Date: 1995	
CY	20	Author: FOLKMAN, J. Title: Tumor Angiogenesis: Therapeutic Implications Publ: <u>New England Journal of Medicine</u> Vol/Iss: 285 (21) Pages: 1182-1186 Date: 11/18/71	
CY	21	Author: PLUM et al. Title: Vaccination with Peptide to the Heparin Binding Domain of bFGF Conjugated to Liposomes Inhibits bFGF Induced Neovascularization (Abstract only) Publ: <u>Proceedings of the American Association for Cancer Research Annual</u> Vol/Iss: 39 Pages: 8 Date: 03/1998	
CY	22	Author: PLUM et al. Title: Administration of a Liposomal FGF-2 Peptide Vaccine Leads to Abrogation of FGF-2-Mediated Angiogenesis and Tumor Development Publ: <u>Vaccine</u> Vol/Iss: 19 (9-10) Pages: 1294-1303 Date: 2000	
CY	23	Author: SEAVER, Sally Title: Monoclonal Antibodies in Industry: More Difficult than Originally Thought Publ: <u>Genetic Engineering News</u> Vol/Iss: 14 Pages: 10 and 21 Date: 08/1994	

Examiner Signature	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006
--------------------	---------------------------------	-----------------	------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	10/799,163
				Filing Date	03/12/2004
				First Named Inventor	John W. Holaday
				Group Art Unit	1653
				Examiner Name	Unassigned
Sheet 4 of 4				Attorney Docket Number	05213-0077 (43170-296614)
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
CY	24	Author: SOKER et al. Title: Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor  Publ: Cell  Vol/Iss: 92 Pages: 735-745 Date: 03/20/1998			
CY	25	Author: TALARICO et al. Title: Protection of Mice Against Tumor Growth by Immunization with an Oncogene-Encoded Growth Factor  Publ: Proceedings of the National Academy of Science USA  Vol/Iss: 87 Pages: 4222-4225 Date: 06/1990			
CY	26	Author: VERMA, ALVING et al. Title: Adjuvant Effects of Liposomes Containing Lipid A: Enhancement of Liposomal Antigen Presentation and Recruitment of Macrophages (Abstract only)  Publ: Infect. Immun.  Vol/Iss: 60 (6) Pages: 2438-2444 Date: 1992			
CY	27	Author: WEBB et al. Title: Cell-Surface Expression and Purification of Human CD-4 Produced in Baculovirus-Infected Insect Cells (Abstract only)  Publ: Proceedings of the National Academy of Science (USA)  Vol/Iss: 86 (20) Pages: 7731-7735 Date: 1989			

Examiner Signature	/Christopher Yaen/ (06/26/2006)	Date Considered	06/26/2006
--------------------	---------------------------------	-----------------	------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.